Tema Oncology ETF (NASDAQ:CANC) Short Interest Update

Tema Oncology ETF (NASDAQ:CANC) was the target of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 1,000 shares, a decline of 37.5% from the October 15th total of 1,600 shares. Based on an average daily trading volume, of 3,200 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Trading of Tema Oncology ETF

An institutional investor recently bought a new position in Tema Oncology ETF stock. Thrivent Financial for Lutherans acquired a new stake in Tema Oncology ETF (NASDAQ:CANC) during the second quarter, according to its most recent filing with the SEC. The firm acquired 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned about 19.01% of Tema Oncology ETF as of its most recent filing with the SEC.

Tema Oncology ETF Stock Down 4.0 %

NASDAQ:CANC traded down $1.10 during mid-day trading on Friday, reaching $26.20. 1,342 shares of the company were exchanged, compared to its average volume of 6,716. The stock has a market cap of $45.58 million, a PE ratio of 26.86 and a beta of 1.11. Tema Oncology ETF has a 12 month low of $22.57 and a 12 month high of $30.11. The company has a fifty day moving average of $28.35 and a 200 day moving average of $28.13.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.